Skip to content

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1)

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) (UNCOVER-2). This study is ongoing, but not recruiting participants. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1). This study is ongoing, but not recruiting participants. A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) (UNCOVER-3). Enrollment: 1346 Study Start Date: July 2012 Estimated Study Completion Date: August 2019 Primary Completion Date: May 2014 (Final data collection date for primary outcome measure) Arms Assigned Interventions Placebo Comparator: Placebo Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12.

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1) 2Epgonline.org Clinical Trial – This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe chronic. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1). A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2). Gov Tue 01 May 2012 This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis. Experimental: 80 mg ixekizumab Dosing Regimen 1 – Experimental: 80 mg ixekizumab Dosing Regimen 2 – Experimental: 80 mg ixekizumab Dosing Regimen 3 – Active Comparator: 50 mg etanercept – Placebo Comparator: Placebo. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Participants were randomly assigned (1:2:2:2) by computer-generated random sequence with an interactive voice response system to receive subcutaneous placebo, etanercept (50 mg twice weekly), or one injection of 80 mg ixekizumab every 2 weeks, or every 4 weeks after a 160 mg starting dose.

A Phase 3 Study in Participants With Moderate to Severe Psoriasis clinicaltrials:NCT01474512 Goto Sponge NotDistinct Permalink. UNCOVER-1. This study will assess the safety and efficacy of LY2439821 compared to placebo in participants with moderate to severe, chronic plaque psoriasis. Cosentyx is approved by the FDA for moderate to severe plaque psoriasis in adults. 3 randomised trials. Lancet 2015;386(9993):54151. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1).

Nct01474512 A Phase 3 Study In Participants With

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1) 3Through this account, we hope to provide members of our psoriasis community with content that is created. Secukinumab treats symptoms of moderate-to-severe plaque psoriasis in certain adults. The study was published in the International Journal of Dermatology entitled Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. At week 12, participants in the UNCOVER-1 study who took ixekizumab showed significantly greater improvements in WPAI-PSO scores when compared to those who took a placebo. Eli Lilly and Company has registered success in phase-three trials in which effect of ixekizumab was assessed as a treatment for moderate-to-severe plaque psoriasis. Although earlier models focused on Th1 cells as the central cell type for psoriasis pathogenesis, newer models focus on the IL-23/Th17 axis 9. The final drug dose was given on week 40, and the participants were followed until week 72. Two phase III studies for moderate-to-severe plaque psoriasis with 80 mg doses given every 2 or 4 weeks show a 77. Study the educational content online or printed out. LILLY’S IXEKIZUMAB FOUND TO BE EFFECTIVE IN PHASE III PSORIASIS STUDIES. Phase III UNCOVER studies in moderate-to- severe plaque psoriasis. In UNCOVER-1, responders to treatment were assigned to continue treatment on placebo or ixekizumab (80mg every four or 12 weeks) for up to 60 weeks. Writing in Arthritis Care and Research, the 16 participants in the 2013 Psoriatic Arthritis Forum outlined three priority actions:. A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2).

About: A Phase 3 Study In Participants With Moderate To Severe Psoriasis

Antibody therapeutics in Phase 3 studies are described, with an emphasis on those with study completion dates in 2014, including antibodies targeting interleukin-17a or the interleukin-17a receptor (secukinumab, ixekizumab, brodalumab), proprotein convertase subtilisin/kexin type 9 (alirocumab, evolocumab, bococizumab), and programmed death 1 receptor (lambrolizumab, nivolumab). In the single-dose study of s.c. administration, 32 participants received placebo (n 8) or 50, 100, 150 or 250 mg (n 6 per dose) of alirocumab.